Cullinan Therapeutics (CGEM) Competitors $12.24 -0.34 (-2.70%) (As of 10:10 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CGEM vs. SPPI, MGNX, IPHA, BDTX, XNCR, VCEL, KYMR, SWTX, GMTX, and ZLABShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Spectrum Pharmaceuticals (SPPI), MacroGenics (MGNX), Innate Pharma (IPHA), Black Diamond Therapeutics (BDTX), Xencor (XNCR), Vericel (VCEL), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Gemini Therapeutics (GMTX), and Zai Lab (ZLAB). These companies are all part of the "medical" sector. Cullinan Therapeutics vs. Spectrum Pharmaceuticals MacroGenics Innate Pharma Black Diamond Therapeutics Xencor Vericel Kymera Therapeutics SpringWorks Therapeutics Gemini Therapeutics Zai Lab Spectrum Pharmaceuticals (NASDAQ:SPPI) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the media refer more to SPPI or CGEM? In the previous week, Cullinan Therapeutics had 7 more articles in the media than Spectrum Pharmaceuticals. MarketBeat recorded 7 mentions for Cullinan Therapeutics and 0 mentions for Spectrum Pharmaceuticals. Cullinan Therapeutics' average media sentiment score of 0.48 beat Spectrum Pharmaceuticals' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Spectrum Pharmaceuticals Neutral Cullinan Therapeutics Neutral Does the MarketBeat Community believe in SPPI or CGEM? Spectrum Pharmaceuticals received 445 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 62.28% of users gave Spectrum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSpectrum PharmaceuticalsOutperform Votes48762.28% Underperform Votes29537.72% Cullinan TherapeuticsOutperform Votes4282.35% Underperform Votes917.65% Do analysts recommend SPPI or CGEM? Cullinan Therapeutics has a consensus price target of $31.67, indicating a potential upside of 158.71%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Spectrum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spectrum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in SPPI or CGEM? 21.7% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 2.7% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, SPPI or CGEM? Spectrum Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Is SPPI or CGEM more profitable? Cullinan Therapeutics' return on equity of -26.54% beat Spectrum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Spectrum PharmaceuticalsN/A -218.44% -66.16% Cullinan Therapeutics N/A -26.54%-25.32% Which has preferable earnings and valuation, SPPI or CGEM? Spectrum Pharmaceuticals has higher earnings, but lower revenue than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Spectrum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpectrum Pharmaceuticals$10.11M20.91-$75.40M-$0.36-2.86Cullinan Therapeutics$18.94M37.63-$153.16M-$2.84-4.31 SummaryCullinan Therapeutics beats Spectrum Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$712.74M$2.95B$5.07B$8.80BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-4.3116.8789.5613.60Price / Sales37.63280.301,224.8087.40Price / CashN/A169.3839.4536.27Price / Book1.144.436.976.33Net Income-$153.16M-$41.63M$119.04M$225.93M7 Day Performance-20.00%-5.15%-1.78%-0.96%1 Month Performance-24.44%-6.91%-3.59%1.06%1 Year Performance41.50%25.64%31.64%26.59% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics1.8429 of 5 stars$12.24-2.7%$31.67+158.7%+43.6%$712.74M$18.94M-4.3130Analyst RevisionSPPISpectrum PharmaceuticalsN/A$1.03flatN/AN/A$211.41M$10.11M-2.8686MGNXMacroGenics3.8708 of 5 stars$3.22-1.8%$7.63+136.8%-57.0%$202.09M$58.75M0.00430IPHAInnate Pharma2.2495 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$136.48M$66.71M0.00220News CoverageGap UpBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.40-1.2%$15.50+545.8%+8.0%$135.79MN/A0.0090Positive NewsXNCRXencor3.5491 of 5 stars$23.69-0.1%$35.75+50.9%+19.3%$1.66B$168.34M-7.41280VCELVericel1.0997 of 5 stars$57.63+0.6%$58.14+0.9%+56.1%$2.84B$197.52M954.49300Analyst ForecastKYMRKymera Therapeutics1.4071 of 5 stars$43.19-2.0%$52.13+20.7%+110.9%$2.80B$78.59M0.00170Analyst ForecastSWTXSpringWorks Therapeutics2.0472 of 5 stars$36.94-1.3%$67.00+81.4%+68.5%$2.75B$5.45M0.00305Analyst ForecastGMTXGemini TherapeuticsN/A$62.55+5.0%N/A+14.7%$2.71BN/A-62.5530ZLABZai Lab2.9675 of 5 stars$26.31+0.3%$52.50+99.5%-7.2%$2.62B$266.72M-9.472,175Analyst Revision Related Companies and Tools Related Companies SPPI Alternatives MGNX Alternatives IPHA Alternatives BDTX Alternatives XNCR Alternatives VCEL Alternatives KYMR Alternatives SWTX Alternatives GMTX Alternatives ZLAB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGEM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CGEM Stock Alerts